Skip to main content
. 2023 Jul 14;8(4):e00147-23. doi: 10.1128/msphere.00147-23

TABLE 1.

Isolation profiles and MICs of clinical isolates

Isolate TA9730 TA9734 TA9759 TA9832
Patient/environment Patient 1 Patient 2 Environment Patient 3
Isolation date 2020.09.02 2020.09.04 2020.09.08 2020.09.09
Gender Female Female N/A c Female
Age (years) 5 5 N/A 4
Origin Feces Feces Waste channel Biliary drain
MIC (µg/mL) a
 Ampicillin-sulbactam >16 R >16 R >16 R >16 R
 Piperacillin-tazobactam >64 R >64 R >64 R >64 R
 Cefazolin >16 R >16 R >16 R >16 R
 Cefotiam b >4 >4 >4 >4
 Cefotaxime >32 R >32 R >32 R >32 R
 Ceftazidime >16 R >16 R >16 R >16 R
 Cefepime >16 R >16 R >16 R >16 R
 Cefmetazole >32 R >32 R >32 R >32 R
 Moxalactam >32 R >32 R >32 R >32 R
 Imipenem >8 R 8 R >8 R 8 R
 Meropenem >8 R >8 R >8 R >8 R
 Doripene >8 R >8 R >8 R >8 R
 Aztreonam ≤1 S ≤1 S ≤1 S ≤1 S
 Gentamicin >8 R >8 R >8 R >8 R
 Tobramycin >8 R >8 R >8 R >8 R
 Amikacin >32 R >32 R >32 R >32 R
 Ciprofloxacin ≤0.06 S 0.5 I ≤0.06 S 0.5 I
 Levofloxacin ≤0.12 S 2 R ≤0.12 S 1 I
 Minocycline ≤1 S 2 S ≤1 S 2 S
 Sulfamethoxazole/trimethoprim >80 R >80 R >80 R >80 R
Carbapenemase production NDM (+) NDM (+) NDM (+) NDM (+)
a

Antibiotic susceptibility as susceptible (S), intermediate (I), or resistant (R) was determined in accordance with the MIC Breakpoints for Enterobacterales in the Clinical and Laboratory Standards Institute criteria (13).

b

There are no criteria for cefotiam (13).

c

N/A, not applicable.

HHS Vulnerability Disclosure